New, Timely, and Practical Information for People Living With Parkinson's Disease
The Web site http://www.ParkinsonsHealth.com, a collaborative effort of Teva Neuroscience, Inc. and Eisai Inc., is designed to offer people living with PD a variety of resources to empower them with knowledge about the disease and strategies for managing it along with their health care providers. The Web site has added a feature entitled, Moving ForwardTM: A practical guide to living with Parkinson's disease. This online patient resource guide, developed in collaboration with some of the top professionals in the field, covers practical information on understanding the disease, how to successfully work with your doctor to manage the symptoms of the disease, how to be your own advocate, and the role the family caregiver may play. This resource is now available for download only on http://www.ParkinsonsHealth.com.
"Managing PD successfully requires a comprehensive approach," says Lawrence Elmer, M.D., Ph.D., director of the Center for Neurological Disorders and the Parkinson's Disease and Movement Disorder Program at the Medical College of Ohio. "The ability to access Moving Forward as an online tool helps to expand the information provided for people with PD and gives them some practical guidelines for living with their disease. It helps people understand that their disease does not have to limit their ability to do the things they want to do, and they can play an active role in managing the disease."
A key component to being actively involved in managing PD is the access to timely information. http://www.ParkinsonsHealth.com now provides PD patients and caregivers the most current information available about the disease through a news service. News stories are updated daily and are related to a variety of PD topics such as clinical research, treatments, medical devices, genetics, exercise, and more. The service also includes a searchable archive of past PD news. This daily news service is exclusive tohttp://www.ParkinsonsHealth.com and continues the Web site's mission of helping people with PD manage their disease. "It is important this Web site be a living and breathing resource that meets both patient and caregiver needs," said Lena Prisco, Ph.D., associate director, Medical Affairs, Eisai Inc. "The addition of this daily news service is another example of our commitment to our human health care (hhc) mission."
"Developing and continuing to strengthen this Web site is a priority for us," said Phyllis Salzman, Ph.D., director, Medical Research, Teva Neuroscience, Inc. "We recognize the importance of empowering patients and caregivers by providing practical, timely information and tools that can help them manage their disease. Both the new daily news service and Moving Forward take important steps in helping people with Parkinson's disease."
PD is a degenerative disorder of the brain that usually initially affects people between the ages of 40 and 70 and affects approximately 1 million Americans. Symptoms can include tremors, stiffness, slowness of movement, and impaired balance.
Teva Neuroscience, Inc. and Eisai Inc. have formed a long-term strategic alliance to offer a new treatment option for people living with Parkinson's disease.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), headquartered in Israel, is among the top 25 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company develops, manufactures, and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Close to 90 percent of Teva's sales are in North America and Europe. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system.
Teva Neuroscience, Inc. is a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.
Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops, and markets products in more than 30 countries. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of more than $1.7 billion (year ended March 31, 2004). Eisai focuses its efforts on four therapeutic areas: neurology, gastrointestinal disorders, oncology, and acute care.
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management of Teva Pharmaceutical Industries Ltd. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products (so called "authorized generics") or successfully extend the exclusivity period of their branded products, the effects of competition on Copaxone® sales, including potential competition from the expected launch of Tysabri®/Antegren®, Teva's ability to rapidly integrate the operations of acquired businesses, including its acquisition of Sicor Inc., regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to completion of appellate litigation, including that relating to Neurontin, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva's ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations outside the United States that may be adversely affected by terrorism or major hostilities, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
http://www.eisai.com
View drug information on Neurontin.
Nou, în timp, ºi de informaþiile practice pentru persoanele care trãiesc cu boala Parkinson - New, Timely, and Practical Information for People Living With Parkinson's Disease - articole medicale engleza - startsanatate